Difference between revisions of "Salgia R, et al. Lung Cancer (2017) cited as Ref 634 in DOI: 10.1038/s41392-020-0110-5 (Q9897)"

From Wikibase.slis.ua.edu
Jump to navigation Jump to search
(‎Created claim: Publication Date (P100): 2017, #quickstatements; #temporary_batch_1590002823654)
(‎Created claim: Page(s) (P105): 7-13, #quickstatements; #temporary_batch_1590074839150)
 
(3 intermediate revisions by the same user not shown)
Property / Published In Name String
 +
Lung Cancer
Property / Published In Name String: Lung Cancer / rank
 +
Normal rank
Property / Volume
 +
105
Property / Volume: 105 / rank
 +
Normal rank
Property / title
 +
A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancer (English)
Property / title: A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancer (English) / rank
 +
Normal rank
Property / Page(s)
 +
7-13
Property / Page(s): 7-13 / rank
 +
Normal rank

Latest revision as of 15:47, 21 May 2020

Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
Language Label Description Also known as
English
Salgia R, et al. Lung Cancer (2017) cited as Ref 634 in DOI: 10.1038/s41392-020-0110-5
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8

    Statements

    Salgia R
    0 references
    0 references
    2017
    0 references
    Lung Cancer
    0 references
    105
    0 references
    A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancer (English)
    0 references
    7-13
    0 references